Enhanced (T)EW-7197 Compositions and Methods for Treating Corneal Endothelial Diseases

The present inventive concept relates to novel compositions and methods utilizing (T)EW-7197 for treating or preventing corneal endothelial diseases, providing improved efficacy, safety, and convenience.

The original patent disclosed the use of (T)EW-7197 for treating or preventing corneal endothelial diseases. However, the existing patent has limitations, such as high dosages, short residence time, and lack of targeted administration. The present inventive concept addresses these limitations by introducing novel compositions and methods that enhance the therapeutic effect of (T)EW-7197 while reducing its required dosage.

The inventive concept comprises four main aspects: 1) a system for targeted administration of (T)EW-7197 to the corneal endothelium using a nano-particle delivery system, reducing the required dosage by at least 50%; 2) a method for combining (T)EW-7197 with a ROCK inhibitor to enhance the therapeutic effect by at least 20%; 3) a pharmaceutical composition incorporating (T)EW-7197 and a mucoadhesive polymer to increase the residence time in the corneal endothelium by at least 2 hours; and 4) a sustained-release formulation of (T)EW-7197 maintaining a therapeutic concentration for at least 7 days. Additionally, a temperature-controlled storage device is provided to enhance the stability of the (T)EW-7197 composition.

The present inventive concept is novel and non-obvious over the original patent as it introduces new compositions and methods that significantly improve the efficacy, safety, and convenience of (T)EW-7197 treatment. The use of nano-particle delivery systems, ROCK inhibitors, mucoadhesive polymers, sustained-release formulations, and temperature-controlled storage devices are all new and unobvious features that overcome the limitations of the original patent.

Alternative embodiments of the inventive concept may include different nano-particle delivery systems, ROCK inhibitors, or mucoadhesive polymers. Variations of the sustained-release formulation may include different polymers or release profiles. Additionally, the temperature-controlled storage device may be replaced with other stabilization methods.

The present inventive concept has significant commercial potential in the ophthalmic industry, particularly for the treatment of corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy and corneal guttata. The improved efficacy, safety, and convenience of the novel compositions and methods are expected to attract significant market share and revenue.